ORPHA:1993
Pai syndrome
Also known as: Median cleft of the upper lip-corpus callosum lipoma-midline facial cutaneous polyps syndrome
Publications
79
44.7th percentile
Trials
0
Interventional, condition-specific
Researchers
419
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare frontonasal characterized by median cleft of the upper lip (MCL), midline polyps of the facial skin, nasal mucosa, and pericallosal lipomas. Hypertelorism with ocular anomalies are also observed, generally with normal neuropsychological development.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0007956
- MeSH:C536135
- OMIM:155145
- UMLS:C1835087
Additional Mondo synonyms (1)
median cleft of the upper lip-corpus callosum lipoma-cutaneous polyps syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
79 matched papers (39 in last 10 years) Source
- Phenotype characterisedPresent
26 HPO annotations (e.g. Downslanted palpebral fissures; Subcutaneous nodule; Nasal polyposis) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
26
Associated phenotypes · MONDO:0007956
- Downslanted palpebral fissures
- Subcutaneous nodule
- Nasal polyposis
- Hypertelorism
- Midline central nervous system lipomas
Showing 5 of 26 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
79
79 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
79 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
39 in the last 10 years · medium confidence · 44.7th percentile (publications denominator)
Phrase hits: 79 · MeSH hits: 0
Who's working on it?
419
Distinct author names in 79 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Savasta S3 papers · 2020
Pediatric Clinic Fondazione IRCCS Policlinico San Matteo University of Pavia Pavia Italy.
Papers in Europe PMC - 02Thauvin-Robinet C3 papers · 2022
Inserm UMR 1231 GAD, Genetics of Developmental disorders, Université de Bourgogne-Franche Comté, FHU TRANSLAD, Dijon, France.
Papers in Europe PMC - 03Alorainy IA2 papers · 2006
Department of Radiology and Diagnostic Imaging, College of Medicine and King Khalid Univerity Hospital, King Saud University, Riyadh, Saudi Arabia. alorainy@ksu.edu.sa
Papers in Europe PMC - 04Amiel J2 papers · 2022
Université Paris Descartes-Sorbonne Paris Cité, Paris, France; Department of Medical Genetics, Hôpital Universitaire Necker-Enfants Malades, Paris, France; Imagine Institute of Genetic Diseases, Université Paris Descartes-Sorbonne Paris Cité, Paris, France.
Papers in Europe PMC - 05Assoum M2 papers · 2022
Inserm UMR 1231 GAD, Genetics of Developmental disorders, Université de Bourgogne-Franche Comté, FHU TRANSLAD, Dijon, France.
Papers in Europe PMC - 06Bruel AL2 papers · 2022
Inserm UMR 1231 GAD, Genetics of Developmental disorders, Université de Bourgogne-Franche Comté, FHU TRANSLAD, Dijon, France. ange-line.bruel@u-bourgogne.fr.
Papers in Europe PMC - 07Callier P2 papers · 2022
Inserm UMR 1231 GAD, Genetics of Developmental disorders, Université de Bourgogne-Franche Comté, FHU TRANSLAD, Dijon, France.
Papers in Europe PMC - 08Chen X2 papers · 2023
Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine, 639 Zhi Zao Ju Rd, Shanghai, 200011, People's Republic of China.
Papers in Europe PMC - 09Duffourd Y2 papers · 2022
Inserm UMR 1231 GAD, Genetics of Developmental disorders, Université de Bourgogne-Franche Comté, FHU TRANSLAD, Dijon, France.
Papers in Europe PMC - 10Faivre L2 papers · 2022
Inserm UMR 1231 GAD, Genetics of Developmental disorders, Université de Bourgogne-Franche Comté, FHU TRANSLAD, Dijon, France.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
medium confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 4 · after dedupe 4 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 4 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (4)
- isrctn·ISRCTN11187912·No longer recruiting·Effect of propionate on mesenteric adipose tissue and insulin sensitivity
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN61785174·No longer recruiting·Metformin improves arterial stiffness in polycystic ovary syndrome (PCOS)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN37849619·No longer recruiting·Effects of pulse incorporation into the diet on components of the metabolic syndrome, body fatness and food habits in women
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN05718824·No longer recruiting·Randomised, double-blind, controlled study of the tranexamic acid prophylaxis efficacy on the development of systemic inflammatory response syndrome and postoperative bleeding in cardiopulmonary bypass surgery patients
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Pai syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Pai syndrome" OR "Median cleft of the upper lip-corpus callosum lipoma-midline facial cutaneous polyps syndrome" OR "Median cleft of upper lip-corpus callosum lipoma-midline facial cutaneous polyps syndrome" OR "median cleft of the upper lip-corpus callosum lipoma-cutaneous polyps syndrome" OR "median cleft of upper lip-corpus callosum lipoma-cutaneous polyps syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Pai syndrome" OR "Median cleft of the upper lip-corpus callosum lipoma-midline facial cutaneous polyps syndrome" OR "Median cleft of upper lip-corpus callosum lipoma-midline facial cutaneous polyps syndrome" OR "median cleft of the upper lip-corpus callosum lipoma-cutaneous polyps syndrome" OR "median cleft of upper lip-corpus callosum lipoma-cutaneous polyps syndrome"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T18:42:00.922Z
